Increased oxidative damage and decreased antioxidant function in aging human substantia nigra compared to striatum: Implications for Parkinson's disease

Neurochemical Research

Volumn 37, Issue 2, 2012, Pages 358-369

  Venkateshappa, C ^a   Harish, G ^a   Mythri, Rajeswara Babu ^a   Mahadevan, Anita ^a   Srinivas Bharath, M M ^a   Shankar, S K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH AND NEUROSCIENCES   (India)

Author keywords

Aging; Caudate nucleus; Glial fibrillary acidic protein; Glutathione; Human brain; Oxidative protein damage; Parkinson's disease; Substantia nigra

Indexed keywords

ANTIOXIDANT; CATALASE; GLIAL FIBRILLARY ACIDIC PROTEIN; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE (UBIQUINONE); SUPEROXIDE DISMUTASE;

ADOLESCENT; ADULT; AGED; AGING; ARTICLE; ASTROCYTE; ASTROCYTOSIS; CAUDATE NUCLEUS; CELL PROLIFERATION; CHILD; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOWN REGULATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN TISSUE; LIPID PEROXIDATION; MESENCEPHALON; NERVE DEGENERATION; OXIDATIVE STRESS; PARKINSON DISEASE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; SCHOOL CHILD; SUBSTANTIA NIGRA; UPREGULATION;

ADULT; AGED; ANTIOXIDANTS; CHILD; CHILD, PRESCHOOL; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; PARKINSON DISEASE; SUBSTANTIA NIGRA; YOUNG ADULT;

EID: 84856372105     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0619-7     Document Type: Article

References (78)

1. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427-442
2. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211 (Pubitemid 36007810)
3. Adams JD Jr, Chang ML, Klaidman L (2001) Parkinson's disease-redox mechanisms. Curr Med Chem 8:809-814
4. MF Beal 1992 Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31 119 130 10.1002/ana.410310202 1349466 10.1002/ana.410310202 1:CAS:528:DyaK38XhsV2itrk%3D Beal MF (1992) Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann Neurol 31:119-130. doi: 10.1002/ana.410310202
5. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD (1992) Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32(Suppl):S82-S87
6. Koiliatsos VE (1998) Parkinson's disease. In: Burke RE (ed) Cell death and disease of the nervous system. Humana Press, Totowa, pp 459-475
7. Sayre LM, Smith MA, Perry G (2001) Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8:721-738 (Pubitemid 32427903)
8. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836 (Pubitemid 19140770)
9. Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB (1991) Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem 56:978-982 (Pubitemid 21922711)
10. Bharath S, Hsu M, Kaur D, Rajagopalan S, Andersen JK (2002) Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64:1037-1048 (Pubitemid 35232279)
11. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 69:1326-1329 (Pubitemid 27364859)
12. Floor E, Wetzel MG (1998) Increased protein oxidation in human substantia nigra pars compacta in comparison with basal ganglia and prefrontal cortex measured with an improved dinitrophenylhydrazine assay. J Neurochem 70:268-275 (Pubitemid 28020852)
13. Good PF, Hsu A, Werner P, Perl DP, Olanow CW (1998) Protein nitration in Parkinson's disease. J Neuropathol Exp Neurol 57:338-342 (Pubitemid 28182632)
14. B Blanchard-Fillion D Prou M Polydoro D Spielberg E Tsika Z Wang SL Hazen M Koval S Przedborski H Ischiropoulos 2006 Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells J Neurosci 26 6124 6130 10.1523/JNEUROSCI.1038-06.2006 16763020 10.1523/JNEUROSCI.1038-06.2006 1:CAS:528:DC%2BD28XmtFSls7g%3D Blanchard-Fillion B, Prou D, Polydoro M, Spielberg D, Tsika E, Wang Z, Hazen SL, Koval M, Przedborski S, Ischiropoulos H (2006) Metabolism of 3-nitrotyrosine induces apoptotic death in dopaminergic cells. J Neurosci 26:6124-6130. doi: 10.1523/JNEUROSCI.1038-06.2006
15. SR Danielson JK Andersen 2008 Oxidative and nitrative protein modifications in Parkinson's disease Free Radic Biol Med 44 1787 1794 10.1016/j.freeradbiomed.2008.03.005 18395015 10.1016/j.freeradbiomed.2008.03.005 1:CAS:528:DC%2BD1cXls1Sisbc%3D Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson's disease. Free Radic Biol Med 44:1787-1794. doi: 10.1016/j.freeradbiomed.2008.03.005
16. Ferrante RJ, Hantraye P, Brouillet E, Beal MF (1999) Increased nitrotyrosine immunoreactivity in substantia nigra neurons in MPTP treated baboons is blocked by inhibition of neuronal nitric oxide synthase. Brain Res 823:177-182 (Pubitemid 29225506)
17. Hasegawa E, Takeshige K, Oishi T, Murai Y, Minakami S (1990) 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem Biophys Res Commun 170:1049-1055 (Pubitemid 20273373)
18. Ischiropoulos H, Beckman JS (2003) Oxidative stress and nitration in neurodegeneration: cause, effect, or association? J Clin Invest 111:163-169 (Pubitemid 36105911)
19. Pennathur S, Jackson-Lewis V, Przedborski S, Heinecke JW (1999) Mass spectrometric quantification of 3-nitrotyrosine, ortho-tyrosine, and o, o′-dityrosine in brain tissue of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mice, a model of oxidative stress in Parkinson's disease. J Biol Chem 274:34621-34628 (Pubitemid 129509499)
20. Keeney PM, Xie J, Capaldi RA, Bennett JP Jr (2006) Parkinson's disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. J Neurosci 26:5256-5264. doi: (Pubitemid 44315308)
21. Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823-827
22. Rogers J, Mastroeni D, Leonard B, Joyce J, Grover A (2007) Neuroinflammation in Alzheimer's disease and Parkinson's disease: are microglia pathogenic in either disorder? Int Rev Neurobiol 82:235-246
23. Werner CJ, Heyny-von Haussen R, Mall G, Wolf S (2008) Proteome analysis of human substantia nigra in Parkinson's disease. Proteome Sci 6:8 (Pubitemid 351385673)
24. RB Mythri C Venkateshappa G Harish A Mahadevan UB Muthane TC Yasha MM Srinivas Bharath SK Shankar 2011 Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains Neurochem Res 36 1452 1463 10.1007/s11064-011-0471-9 21484266 10.1007/s11064-011-0471-9 1:CAS:528:DC%2BC3MXksFWntbg%3D Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, Shankar SK (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains. Neurochem Res 36:1452-1463. doi: 10.1007/s11064-011-0471-9
25. Karunakaran S, Saeed U, Ramakrishnan S, Koumar RC, Ravindranath V (2007) Constitutive expression and functional characterization of mitochondrial glutaredoxin (Grx2) in mouse and human brain. Brain Res 1185:8-17. doi: (Pubitemid 350176571)
26. S Karunakaran U Saeed M Mishra RK Valli SD Joshi DP Meka P Seth V Ravindranath 2008 Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice J Neurosci 28 12500 12509 10.1523/jneurosci.4511-08.2008 19020042 10.1523/JNEUROSCI.4511-08. 2008 1:CAS:528:DC%2BD1cXhsVGmtLbO Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, Seth P, Ravindranath V (2008) Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated mice. J Neurosci 28:12500-12509. doi: 10.1523/jneurosci.4511-08.2008
27. PA Alladi A Mahadevan TC Yasha TR Raju SK Shankar U Muthane 2009 Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease Neuroscience 159 236 245 10.1016/j.neuroscience.2008.11.051 19135503 10.1016/j.neuroscience.2008.11.051 1:CAS:528:DC%2BD1MXit1Orsb8%3D Alladi PA, Mahadevan A, Yasha TC, Raju TR, Shankar SK, Muthane U (2009) Absence of age-related changes in nigral dopaminergic neurons of Asian Indians: relevance to lower incidence of Parkinson's disease. Neuroscience 159:236-245. doi: 10.1016/j.neuroscience.2008. 11.051
28. Chinta SJ, Kommaddi RP, Turman CM, Strobel HW, Ravindranath V (2005) Constitutive expression and localization of cytochrome P-450 1A1 in rat and human brain: presence of a splice variant form in human brain. J Neurochem 93:724-736. doi: (Pubitemid 40617632)
29. V Agarwal RP Kommaddi K Valli D Ryder TM Hyde JE Kleinman HW Strobel V Ravindranath 2008 Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite PLoS One 3 e2337 10.1371/journal.pone.0002337 18545703 10.1371/journal.pone.0002337 Agarwal V, Kommaddi RP, Valli K, Ryder D, Hyde TM, Kleinman JE, Strobel HW, Ravindranath V (2008) Drug metabolism in human brain: high levels of cytochrome P4503A43 in brain and metabolism of anti-anxiety drug alprazolam to its active metabolite. PLoS One 3:e2337. doi: 10.1371/journal. pone.0002337
30. Chandana R, Mythri RB, Mahadevan A, Shankar SK, Srinivas Bharath MM (2009) Biochemical analysis of protein stability in human brain collected at different post-mortem intervals. Indian J Med Res 129:189-199
31. PA Alladi A Mahadevan SK Shankar TR Raju U Muthane 2010 Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians J Chem Neuroanat 40 43 52 10.1016/j.jchemneu.2010.03.007 20347960 10.1016/j.jchemneu.2010.03.007 1:CAS:528:DC%2BC3cXlsFWisLs%3D Alladi PA, Mahadevan A, Shankar SK, Raju TR, Muthane U (2010) Expression of GDNF receptors GFRalpha1 and RET is preserved in substantia nigra pars compacta of aging Asian Indians. J Chem Neuroanat 40:43-52. doi: 10.1016/j.jchemneu.2010.03. 007
32. PA Alladi A Mahadevan K Vijayalakshmi U Muthane SK Shankar TR Raju 2010 Ageing enhances alpha-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians Neurochem Int 57 530 539 10.1016/j.neuint.2010.06.018 20615443 10.1016/j.neuint.2010.06.018 1:CAS:528:DC%2BC3cXhtFalsLvI Alladi PA, Mahadevan A, Vijayalakshmi K, Muthane U, Shankar SK, Raju TR (2010) Ageing enhances alpha-synuclein, ubiquitin and endoplasmic reticular stress protein expression in the nigral neurons of Asian Indians. Neurochem Int 57:530-539. doi: 10.1016/j.neuint.2010.06.018
33. B Jagatha RB Mythri S Vali MM Bharath 2008 Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies Free Radic Biol Med 44 907 917 10.1016/j.freeradbiomed.2007.11.011 18166164 10.1016/j.freeradbiomed.2007.11.011 1:CAS:528:DC%2BD1cXhslGrt78%3D Jagatha B, Mythri RB, Vali S, Bharath MM (2008) Curcumin treatment alleviates the effects of glutathione depletion in vitro and in vivo: therapeutic implications for Parkinson's disease explained via in silico studies. Free Radic Biol Med 44:907-917. doi: 10.1016/j.freeradbiomed.2007.11.011
34. Ohkawa H, Ohishi N, Yagi K (1979) Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 95:351-358 (Pubitemid 9194347)
35. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121-126
36. Bagnyukova TV, Storey KB, Lushchak VI (2003) Induction of oxidative stress in Rana ridibunda during recovery from winter hibernation. J Therm Biol 28:21-28 (Pubitemid 36164273)
37. Tietze F (1969) Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 27:502-522
38. Flohe L, Gunzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114-121 (Pubitemid 14165378)
39. Carlberg I, Mannervik B (1985) Glutathione reductase. Methods Enzymol 113:484-490 (Pubitemid 16195819)
40. Guthenberg C, Alin P, Mannervik B (1985) Glutathione transferase from rat testis. Methods Enzymol 113:507-510 (Pubitemid 16195824)
41. Mythri RB, Jagatha B, Pradhan N, Andersen J, Bharath MM (2007) Mitochondrial complex I inhibition in Parkinson's disease: how can curcumin protect mitochondria? Antioxid Redox Signal 9:399-408. doi: (Pubitemid 46145986)
42. Trounce IA, Kim YL, Jun AS, Wallace DC (1996) Assessment of mitochondrial oxidative phosphorylation in patient muscle biopsies, lymphoblasts, and transmitochondrial cell lines. Methods Enzymol 264:484-509 (Pubitemid 26089333)
43. Albers DS, Beal MF (2000) Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J Neural Transm Suppl 59:133-154 (Pubitemid 30479414)
44. R Banerjee AA Starkov MF Beal B Thomas 2009 Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis Biochim Biophys Acta 1792 651 663 10.1016/j.bbadis.2008.11.007 19059336 1:CAS:528:DC%2BD1MXnsFygs74%3D Banerjee R, Starkov AA, Beal MF, Thomas B (2009) Mitochondrial dysfunction in the limelight of Parkinson's disease pathogenesis. Biochim Biophys Acta 1792:651-663. doi: 10.1016/j.bbadis.2008.11.007
45. Lin MT, Beal MF (2006) Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 443:787-795. doi: (Pubitemid 44622683)
46. Schapira AH, Cooper JM, Dexter D, Jenner P, Clark JB, Marsden CD (1989) Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1:1269 (Pubitemid 19140359)
47. Damier P, Hirsch EC, Zhang P, Agid Y, Javoy-Agid F (1993) Glutathione peroxidase, glial cells and Parkinson's disease. Neuroscience 52:1-6 (Pubitemid 23026600)
48. Jenner P (1993) Altered mitochondrial function, iron metabolism and glutathione levels in Parkinson's disease. Acta Neurol Scand 146(Suppl):6-13 (Pubitemid 23251601)
49. Kolosova NG, Shcheglova TV, Amstislavskaya TG, Loskutova LV (2003) Comparative analysis of LPO products in brain structures of Wistar and OXYS rats of different age. Bull Exp Biol Med 135:593-596 (Pubitemid 37368993)
50. Mizuno Y, Ohta K (1986) Regional distributions of thiobarbituric acid-reactive products, activities of enzymes regulating the metabolism of oxygen free radicals, and some of the related enzymes in adult and aged rat brains. J Neurochem 46:1344-1352 (Pubitemid 16062529)
51. Anglade P, Vyas S, Hirsch EC, Agid Y (1997) Apoptosis in dopaminergic neurons of the human substantia nigra during normal aging. Histol Histopathol 12:603-610 (Pubitemid 27314689)
52. DJ Surmeier JN Guzman J Sanchez-Padilla JA Goldberg 2011 The origins of oxidant stress in Parkinson's disease and therapeutic strategies Antioxid Redox Signal 14 1289 1301 10.1089/ars.2010.3521 20712409 10.1089/ars.2010.3521 1:CAS:528:DC%2BC3MXivVGjtrY%3D Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA (2011) The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antioxid Redox Signal 14:1289-1301. doi: 10.1089/ars.2010.3521
53. KL Double S Reyes EL Werry GM Halliday 2010 Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92 316 329 10.1016/j.pneurobio.2010.06.001 20541584 10.1016/j.pneurobio.2010.06.001 1:STN:280:DC%2BC3cbms1Cqtw%3D%3D Double KL, Reyes S, Werry EL, Halliday GM (2010) Selective cell death in neurodegeneration: why are some neurons spared in vulnerable regions? Prog Neurobiol 92:316-329. doi: 10.1016/j.pneurobio.2010.06.001
54. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP (1988) Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 25:419-438
55. Kish SJ, Shannak K, Rajput A, Deck JH, Hornykiewicz O (1992) Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem 58:642-648
56. Riederer BM (1989) Antigen preservation tests for immunocytochemical detection of cytoskeletal proteins: influence of aldehyde fixatives. J Histochem Cytochem 37:675-681 (Pubitemid 19112403)
57. Sofic E, Lange KW, Jellinger K, Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett 142:128-130
58. Frade J, Pope S, Schmidt M, Dringen R, Barbosa R, Pocock J, Laranjinha J, Heales S (2008) Glutamate induces release of glutathione from cultured rat astrocytes-a possible neuroprotective mechanism? J Neurochem 105:1144-1152. doi: (Pubitemid 351590782)
59. Mann VM, Cooper JM, Daniel SE, Srai K, Jenner P, Marsden CD, Schapira AH (1994) Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol 36:876-881. doi: (Pubitemid 24370927)
60. Ciriolo MR, Fiskin K, De Martino A, Corasaniti MT, Nistico G, Rotilio G (1991) Age-related changes in Cu, Zn superoxide dismutase, Se-dependent and -independent glutathione peroxidase and catalase activities in specific areas of rat brain. Mech Ageing Dev 61:287-297
61. Carrillo MC, Kanai S, Sato Y, Kitani K (1992) Age-related changes in antioxidant enzyme activities are region and organ, as well as sex, selective in the rat. Mech Ageing Dev 65:187-198
62. Benzi G, Pastoris O, Marzatico F, Villa RF (1989) Cerebral enzyme antioxidant system. Influence of aging and phosphatidylcholine. J Cereb Blood Flow Metab 9:373-380 (Pubitemid 19134814)
63. McGeer PL, Itagaki S, Boyes BE, McGeer EG (1988) Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 38:1285-1291
64. Banati RB, Daniel SE, Blunt SB (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 13:221-227. doi: (Pubitemid 28127795)
65. Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 260:1130-1132 (Pubitemid 23186789)
66. Uchida K, Kihara N, Hashimoto K, Nakayama H, Yamaguchi R, Tateyama S (2003) Age-related histological changes in the canine substantia nigra. J Vet Med Sci 65:179-185 (Pubitemid 41389971)
67. O'Callaghan JP, Miller DB (1991) The concentration of glial fibrillary acidic protein increases with age in the mouse and rat brain. Neurobiol Aging 12:171-174
68. Castillo-Ruiz MM, Campuzano O, Acarin L, Castellano B, Gonzalez B (2007) Delayed neurodegeneration and early astrogliosis after excitotoxicity to the aged brain. Exp Gerontol 42:343-354. doi: (Pubitemid 46371354)
69. A Ciesielska I Joniec I Kurkowska-Jastrzebska A Cudna A Przybylkowski A Czlonkowska A Czlonkowski 2009 The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease Inflamm Res 58 747 753 10.1007/s00011-009-0026-6 19777158 10.1007/s00011-009-0026-6 1:CAS:528:DC%2BD1MXht1eksLbM Ciesielska A, Joniec I, Kurkowska-Jastrzebska I, Cudna A, Przybylkowski A, Czlonkowska A, Czlonkowski A (2009) The impact of age and gender on the striatal astrocytes activation in murine model of Parkinson's disease. Inflamm Res 58:747-753. doi: 10.1007/s00011-009-0026-6
70. Miller DB, O'Callaghan JP, Ali SF (2000) Age as a susceptibility factor in the striatal dopaminergic neurotoxicity observed in the mouse following substituted amphetamine exposure. Ann N Y Acad Sci 914:194-207
71. Gordon MN, Schreier WA, Ou X, Holcomb LA, Morgan DG (1997) Exaggerated astrocyte reactivity after nigrostriatal deafferentation in the aged rat. J Comp Neurol 388:106-119 (Pubitemid 27485635)
72. Dluzen DE, Disshon KA, McDermott JL (1998) Estrogen as a modulator of striatal dopaminergic neurotoxicity. In: Marwah J, Teitelbaum H (eds) Advances in neurodegenerative disorders, vol 1: Parkinson's disease. Prominent Press, Scottsdale, pp 149-192
73. Lichtensteiger W (1969) Cyclic variations of catecholamine content in hypothalamic nerve cells during the estrous cycle of the rat, with a concomitant study of the substantia nigra. J Pharmacol Exp Ther 165:204-215
74. Kenchappa RS, Diwakar L, Annepu J, Ravindranath V (2004) Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration. FASEB J 18:1102-1104 (Pubitemid 39561537)
75. Liu B, Dluzen DE (2007) Oestrogen and nigrostriatal dopaminergic neurodegeneration: animal models and clinical reports of Parkinson's disease. Clin Exp Pharmacol Physiol 34:555-565 (Pubitemid 46953100)
76. Currie LJ, Harrison MB, Trugman JM, Bennett JP, Wooten GF (2004) Postmenopausal estrogen use affects risk for Parkinson disease. Arch Neurol 61:886-888 (Pubitemid 38747327)
77. Bedard P, Langelier P, Villeneuve A (1977) Oestrogens and extrapyramidal system. Lancet 2:1367-1368 (Pubitemid 8258610)
78. Koller WC, Barr A, Biary N (1982) Estrogen treatment of dyskinetic disorders. Neurology 32:547-549 (Pubitemid 12161359)